JPS59167587A - オメプラゾ−ル化合物 - Google Patents
オメプラゾ−ル化合物Info
- Publication number
- JPS59167587A JPS59167587A JP59038921A JP3892184A JPS59167587A JP S59167587 A JPS59167587 A JP S59167587A JP 59038921 A JP59038921 A JP 59038921A JP 3892184 A JP3892184 A JP 3892184A JP S59167587 A JPS59167587 A JP S59167587A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- onoprazole
- mammals
- humans
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960000381 omeprazole Drugs 0.000 title claims description 4
- -1 Omeprazole compound Chemical class 0.000 title description 6
- 150000001875 compounds Chemical group 0.000 claims description 36
- 238000002360 preparation method Methods 0.000 claims description 20
- 241000124008 Mammalia Species 0.000 claims description 14
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 11
- 125000004432 carbon atom Chemical group C* 0.000 claims description 7
- 150000001768 cations Chemical class 0.000 claims description 7
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- 230000002496 gastric effect Effects 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- 206010064147 Gastrointestinal inflammation Diseases 0.000 claims description 4
- 230000027119 gastric acid secretion Effects 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 210000004211 gastric acid Anatomy 0.000 claims 1
- 150000002736 metal compounds Chemical class 0.000 claims 1
- 230000001228 trophic effect Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 description 28
- 150000003839 salts Chemical class 0.000 description 25
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 23
- 239000000243 solution Substances 0.000 description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 22
- 159000000000 sodium salts Chemical class 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 238000009472 formulation Methods 0.000 description 11
- 239000002775 capsule Substances 0.000 description 10
- 239000000843 powder Substances 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- 238000003756 stirring Methods 0.000 description 10
- 239000003826 tablet Substances 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 239000008367 deionised water Substances 0.000 description 9
- 229910021641 deionized water Inorganic materials 0.000 description 9
- 239000013543 active substance Substances 0.000 description 8
- 230000007935 neutral effect Effects 0.000 description 7
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 239000002702 enteric coating Substances 0.000 description 5
- 238000009505 enteric coating Methods 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- DZLFLBLQUQXARW-UHFFFAOYSA-N tetrabutylammonium Chemical class CCCC[N+](CCCC)(CCCC)CCCC DZLFLBLQUQXARW-UHFFFAOYSA-N 0.000 description 5
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 230000001120 cytoprotective effect Effects 0.000 description 4
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 4
- 235000019799 monosodium phosphate Nutrition 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000008223 sterile water Substances 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 3
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 159000000003 magnesium salts Chemical class 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 239000010936 titanium Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 229920000832 Cutin Polymers 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- 241000792859 Enema Species 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical group ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000007920 enema Substances 0.000 description 2
- 229940079360 enema for constipation Drugs 0.000 description 2
- 239000002662 enteric coated tablet Substances 0.000 description 2
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 2
- 239000012065 filter cake Substances 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- SHFJWMWCIHQNCP-UHFFFAOYSA-M hydron;tetrabutylazanium;sulfate Chemical compound OS([O-])(=O)=O.CCCC[N+](CCCC)(CCCC)CCCC SHFJWMWCIHQNCP-UHFFFAOYSA-M 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 239000012669 liquid formulation Substances 0.000 description 2
- 229910003002 lithium salt Inorganic materials 0.000 description 2
- DCUGZOBNIZLALZ-UHFFFAOYSA-N magnesium;dihydrate Chemical compound O.O.[Mg] DCUGZOBNIZLALZ-UHFFFAOYSA-N 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- RUNIEFCRNHEYJO-UHFFFAOYSA-N oxolane;sodium Chemical compound [Na].C1CCOC1 RUNIEFCRNHEYJO-UHFFFAOYSA-N 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
- 235000019204 saccharin Nutrition 0.000 description 2
- 229940081974 saccharin Drugs 0.000 description 2
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000004334 sorbic acid Substances 0.000 description 2
- 229940075582 sorbic acid Drugs 0.000 description 2
- 235000010199 sorbic acid Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 229960004793 sucrose Drugs 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- ZXUCBXRTRRIBSO-UHFFFAOYSA-L tetrabutylazanium;sulfate Chemical compound [O-]S([O-])(=O)=O.CCCC[N+](CCCC)(CCCC)CCCC.CCCC[N+](CCCC)(CCCC)CCCC ZXUCBXRTRRIBSO-UHFFFAOYSA-L 0.000 description 2
- 150000003608 titanium Chemical class 0.000 description 2
- 229910052719 titanium Inorganic materials 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- WPWHSFAFEBZWBB-UHFFFAOYSA-N 1-butyl radical Chemical compound [CH2]CCC WPWHSFAFEBZWBB-UHFFFAOYSA-N 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- IIVWHGMLFGNMOW-UHFFFAOYSA-N 2-methylpropane Chemical compound C[C](C)C IIVWHGMLFGNMOW-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 101100219382 Caenorhabditis elegans cah-2 gene Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- ARLZGEXVMUDUQZ-UHFFFAOYSA-N O.O.[Ca] Chemical compound O.O.[Ca] ARLZGEXVMUDUQZ-UHFFFAOYSA-N 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 206010046274 Upper gastrointestinal haemorrhage Diseases 0.000 description 1
- SAHIZENKTPRYSN-UHFFFAOYSA-N [2-[3-(phenoxymethyl)phenoxy]-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound O(C1=CC=CC=C1)CC=1C=C(OC2=NC(=CC(=C2)CN)C(F)(F)F)C=CC=1 SAHIZENKTPRYSN-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003831 antifriction material Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 101150027026 cct4 gene Proteins 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000007931 coated granule Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- MJFQUUWPZOGYQT-UHFFFAOYSA-O diaminomethylideneazanium;nitrate Chemical compound NC(N)=[NH2+].[O-][N+]([O-])=O MJFQUUWPZOGYQT-UHFFFAOYSA-O 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 201000000052 gastrinoma Diseases 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-O guanidinium Chemical compound NC(N)=[NH2+] ZRALSGWEFCBTJO-UHFFFAOYSA-O 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- HZZOEADXZLYIHG-UHFFFAOYSA-N magnesiomagnesium Chemical compound [Mg][Mg] HZZOEADXZLYIHG-UHFFFAOYSA-N 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 230000001254 nonsecretory effect Effects 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 235000020374 simple syrup Nutrition 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 150000005621 tetraalkylammonium salts Chemical class 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Compounds Of Unknown Constitution (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
- Medicines Containing Plant Substances (AREA)
- Saccharide Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Cephalosporin Compounds (AREA)
- Inorganic Insulating Materials (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE8301182-5 | 1983-03-04 | ||
| SE8301182A SE8301182D0 (sv) | 1983-03-04 | 1983-03-04 | Novel compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS59167587A true JPS59167587A (ja) | 1984-09-21 |
| JPH0313233B2 JPH0313233B2 (enExample) | 1991-02-22 |
Family
ID=20350251
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP59038921A Granted JPS59167587A (ja) | 1983-03-04 | 1984-03-02 | オメプラゾ−ル化合物 |
Country Status (43)
Cited By (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS62258320A (ja) * | 1986-04-30 | 1987-11-10 | Yoshitomi Pharmaceut Ind Ltd | 内服用新規医薬製剤 |
| JPS62277322A (ja) * | 1986-02-13 | 1987-12-02 | Takeda Chem Ind Ltd | 安定化された腸溶性抗潰瘍固形組成物 |
| JPH02138213A (ja) * | 1988-08-18 | 1990-05-28 | Takeda Chem Ind Ltd | 注射剤 |
| US5433959A (en) * | 1986-02-13 | 1995-07-18 | Takeda Chemical Industries, Ltd. | Stabilized pharmaceutical composition |
| JP2002114779A (ja) * | 2000-08-04 | 2002-04-16 | Takeda Chem Ind Ltd | ベンズイミダゾール化合物の塩およびその用途 |
| JP2003512327A (ja) * | 1999-10-22 | 2003-04-02 | アストラゼネカ・アクチエボラーグ | 置換ベンズイミダゾール製剤 |
| US6749864B2 (en) | 1986-02-13 | 2004-06-15 | Takeda Chemical Industries, Ltd. | Stabilized pharmaceutical composition |
| WO2004085424A1 (ja) * | 2003-03-24 | 2004-10-07 | Eisai Co., Ltd. | スルホキシド誘導体またはその塩のアモルファスの製造方法 |
| JP2005521693A (ja) * | 2002-03-05 | 2005-07-21 | アストラゼネカ・アクチエボラーグ | オメプラゾール及びエソメプラゾールのアルキルアンモニウム塩 |
| JP2006519224A (ja) * | 2003-02-24 | 2006-08-24 | 三菱ウェルファーマ株式会社 | テナトプラゾールの光学異性体および治療におけるその使用 |
| JP2007504223A (ja) * | 2003-09-04 | 2007-03-01 | アストラゼネカ・アクチエボラーグ | オメプラゾール及びエソメプラゾールｉｉの新規な塩 |
| JP2007504222A (ja) * | 2003-09-04 | 2007-03-01 | アストラゼネカ・アクチエボラーグ | オメプラゾール及びエソメプラゾールｉの新規な塩 |
| JP2007161734A (ja) * | 1997-05-30 | 2007-06-28 | Astrazeneca Ab | Ｓ−オメプラゾールの新規な形態 |
| JP2008502665A (ja) * | 2004-06-17 | 2008-01-31 | シデム ファーマ ソシエテ アノニム | Ｓ−テナトプラゾールナトリウム塩一水和物及び治療におけるその使用 |
| JP2008545768A (ja) * | 2005-06-08 | 2008-12-18 | レツク・フアーマシユーテイカルズ・デー・デー | オメプラゾールナトリウムの結晶性溶媒和物 |
| JP2009513625A (ja) * | 2005-10-26 | 2009-04-02 | ハンミ ファーム． シーオー．， エルティーディー． | Ｓ−オメプラゾールストロンチウム塩またはその水和物、その製造方法、及びこれを含む医薬組成物 |
| JP2009539830A (ja) * | 2006-06-07 | 2009-11-19 | アストラゼネカ・アクチエボラーグ | エソメプラゾールのアンモニウム塩の新規な製造方法 |
| JP2010054398A (ja) * | 2008-08-29 | 2010-03-11 | Seiko Clock Inc | 装飾装置及びからくり時計 |
| US8513426B2 (en) | 2005-10-26 | 2013-08-20 | Hanmi Science Co., Ltd | Crystalline S-omeprazole strontium hydrate, method for preparing same, and pharmaceutical composition containing same |
Families Citing this family (140)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5869513A (en) * | 1985-05-24 | 1999-02-09 | G. D. Searle & Co. | 2- (1H-benzimidazol-2-ylsulfinyl)methyl!benzenamines |
| EP0204215B1 (en) | 1985-05-24 | 1993-08-11 | G.D. Searle & Co. | 2-[(1H-benzimidazol-2-ylsulfinyl)methyl]-benzenamines |
| CA1327010C (en) * | 1986-02-13 | 1994-02-15 | Tadashi Makino | Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production |
| GB2189699A (en) * | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated acid-labile medicaments |
| US4687775A (en) * | 1986-07-17 | 1987-08-18 | G. D. Searle & Co. | 2-[(Imidazo[1,2-a]pyridinylmethyl)sulfinyl]-1H-benzimidazoles |
| US4772619A (en) * | 1986-07-17 | 1988-09-20 | G. D. Searle & Co. | [(1H-benzimidazol-2-ylsulfinyl)methyl]-2-pyridinamines |
| US4721718A (en) * | 1986-08-18 | 1988-01-26 | G. D. Searle & Co. | 2-[(imidazo[1,2-a]pyridin-3-ylmethyl)sulfinyl]-1H-benzimidazoles useful in the treatment and prevention of ulcers |
| KR920003928B1 (ko) * | 1988-09-20 | 1992-05-18 | 히사미쯔세이야꾸 가부시기가이샤 | 신규의 디벤즈[b,e]옥세핀유도체 |
| EG19302A (en) * | 1988-12-22 | 1994-11-30 | Haessle Ab | Compound with gastric acid inhibitory effect and process for its preparation |
| SE8804629D0 (sv) | 1988-12-22 | 1988-12-22 | Ab Haessle | New therapeutically active compounds |
| JP2694361B2 (ja) * | 1989-02-09 | 1997-12-24 | アストラ アクチエボラグ | 抗菌剤 |
| US5049674A (en) * | 1989-12-20 | 1991-09-17 | Aktiebolaget Hassle | Therapeutically active fluoro substituted benzimidazoles |
| US5274099A (en) * | 1989-12-20 | 1993-12-28 | Aktiebolaget Hassle | Therapeutically active fluoro substituted benzimidazoles |
| US4965269A (en) * | 1989-12-20 | 1990-10-23 | Ab Hassle | Therapeutically active chloro substituted benzimidazoles |
| SE9002206D0 (sv) | 1990-06-20 | 1990-06-20 | Haessle Ab | New compounds |
| ES2026761A6 (es) * | 1990-10-31 | 1992-05-01 | Genesis Para La Investigacion | Procedimiento de obtencion del omeprazol. |
| ATE144421T1 (de) * | 1992-07-28 | 1996-11-15 | Astra Ab | Injizierbares arzneimittel und satz, die omoprazol oder verwandte verbindungenenthalten |
| SE9301830D0 (sv) * | 1993-05-28 | 1993-05-28 | Ab Astra | New compounds |
| US6875872B1 (en) | 1993-05-28 | 2005-04-05 | Astrazeneca | Compounds |
| SE9302395D0 (sv) * | 1993-07-09 | 1993-07-09 | Ab Astra | New pharmaceutical formulation |
| SE9302396D0 (sv) * | 1993-07-09 | 1993-07-09 | Ab Astra | A novel compound form |
| TW359614B (en) * | 1993-08-31 | 1999-06-01 | Takeda Chemical Industries Ltd | Composition containing benzimidazole compounds for rectal administration |
| TW280770B (enExample) | 1993-10-15 | 1996-07-11 | Takeda Pharm Industry Co Ltd | |
| DE723436T1 (de) * | 1994-07-08 | 1997-09-11 | Astra Ab | Aus mehreren einzeleinheiten zusammengesetzte dosierungsform in tablettenform (i) |
| GB9423968D0 (en) * | 1994-11-28 | 1995-01-11 | Astra Ab | Resolution |
| CN1042423C (zh) * | 1995-05-25 | 1999-03-10 | 常州市第四制药厂 | 奥美拉唑盐水合物及其制备方法 |
| US6645988B2 (en) | 1996-01-04 | 2003-11-11 | Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
| US5840737A (en) | 1996-01-04 | 1998-11-24 | The Curators Of The University Of Missouri | Omeprazole solution and method for using same |
| US6489346B1 (en) | 1996-01-04 | 2002-12-03 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
| US6699885B2 (en) * | 1996-01-04 | 2004-03-02 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and methods of using same |
| SE508669C2 (sv) * | 1996-04-26 | 1998-10-26 | Astra Ab | Nytt förfarande |
| SE510666C2 (sv) * | 1996-12-20 | 1999-06-14 | Astra Ab | Nya Kristallmodifikationer |
| SE9702000D0 (sv) * | 1997-05-28 | 1997-05-28 | Astra Ab | New pharmaceutical formulation |
| US6747155B2 (en) | 1997-05-30 | 2004-06-08 | Astrazeneca Ab | Process |
| SE510643C2 (sv) * | 1997-06-27 | 1999-06-14 | Astra Ab | Termodynamiskt stabil omeprazol natrium form B |
| SI9700186B (sl) | 1997-07-14 | 2006-10-31 | Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. | Nova farmacevtska oblika z nadzorovanim sproscanjem zdravilnih ucinkovin |
| US6096340A (en) * | 1997-11-14 | 2000-08-01 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
| US6174548B1 (en) | 1998-08-28 | 2001-01-16 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
| SE9704870D0 (sv) * | 1997-12-22 | 1997-12-22 | Astra Ab | New pharmaceutical formulation I |
| SE9704869D0 (sv) * | 1997-12-22 | 1997-12-22 | Astra Ab | New pharmaceutical formulaton II |
| DE19801811B4 (de) * | 1998-01-19 | 2004-12-23 | Stada Arzneimittel Ag | Pharmazeutische Zubereitung zur oralen Verabreichung |
| DK173431B1 (da) | 1998-03-20 | 2000-10-23 | Gea Farmaceutisk Fabrik As | Farmaceutisk formulering omfattende en 2-[[(2-pyridinyl)methyl]sulfinyl]benzimidazol med anti-ulcusaktivitet samt fremgangs |
| US6048981A (en) * | 1998-04-22 | 2000-04-11 | Torcan Chemical Ltd. | Magnesium omeprazole and process for its preparation |
| US6733778B1 (en) | 1999-08-27 | 2004-05-11 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
| SE9803772D0 (sv) | 1998-11-05 | 1998-11-05 | Astra Ab | Pharmaceutical formulation |
| UA72748C2 (en) | 1998-11-10 | 2005-04-15 | Astrazeneca Ab | A novel crystalline form of omeprazole |
| IL142703A (en) * | 1998-11-10 | 2006-04-10 | Astrazeneca Ab | Crystalline form of omeprazole |
| SE9900274D0 (sv) * | 1999-01-28 | 1999-01-28 | Astra Ab | New compound |
| IL130602A0 (en) | 1999-06-22 | 2000-06-01 | Dexcel Ltd | Stable benzimidazole formulation |
| US6780880B1 (en) | 1999-08-26 | 2004-08-24 | Robert R. Whittle | FT-Raman spectroscopic measurement |
| US6262085B1 (en) | 1999-08-26 | 2001-07-17 | Robert R. Whittle | Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same |
| US6312712B1 (en) | 1999-08-26 | 2001-11-06 | Robert R. Whittle | Method of improving bioavailability |
| US6268385B1 (en) | 1999-08-26 | 2001-07-31 | Robert R. Whittle | Dry blend pharmaceutical formulations |
| US6369087B1 (en) | 1999-08-26 | 2002-04-09 | Robert R. Whittle | Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same |
| US6326384B1 (en) | 1999-08-26 | 2001-12-04 | Robert R. Whittle | Dry blend pharmaceutical unit dosage form |
| US6316020B1 (en) * | 1999-08-26 | 2001-11-13 | Robert R. Whittle | Pharmaceutical formulations |
| US6312723B1 (en) | 1999-08-26 | 2001-11-06 | Robert R. Whittle | Pharmaceutical unit dosage form |
| US6262086B1 (en) | 1999-08-26 | 2001-07-17 | Robert R. Whittle | Pharmaceutical unit dosage form |
| US6228400B1 (en) | 1999-09-28 | 2001-05-08 | Carlsbad Technology, Inc. | Orally administered pharmaceutical formulations of benzimidazole derivatives and the method of preparing the same |
| CA2290893C (en) * | 1999-11-16 | 2007-05-01 | Bernard Charles Sherman | Magnesium omeprazole |
| DE19959419A1 (de) | 1999-12-09 | 2001-06-21 | Ratiopharm Gmbh | Stabile galenische Zubereitungen umfassend ein Benzimidazol und Verfahren zu ihrer Herstellung |
| US7732404B2 (en) | 1999-12-30 | 2010-06-08 | Dexcel Ltd | Pro-nanodispersion for the delivery of cyclosporin |
| BR0110926A (pt) * | 2000-05-15 | 2004-02-17 | Ranbaxy Lab Ltd | Novas formas amorfas de sais de omeprazol e processo de preparação dos mesmos |
| US6306435B1 (en) | 2000-06-26 | 2001-10-23 | Yung Shin Pharmaceutical Industrial Co. Ltd. | Oral pharmaceutical preparation embedded in an oily matrix and methods of making the same |
| CA2386716C (en) * | 2002-05-17 | 2012-07-24 | Bernard Charles Sherman | Magnesium salt of s-omeprazole |
| MY137726A (en) | 2000-11-22 | 2009-03-31 | Nycomed Gmbh | Freeze-dried pantoprazole preparation and pantoprazole injection |
| US8206741B2 (en) | 2001-06-01 | 2012-06-26 | Pozen Inc. | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
| WO2003063840A2 (en) * | 2002-01-25 | 2003-08-07 | Santarus, Inc. | Transmucosal delivery of proton pump inhibitors |
| TW200410955A (en) | 2002-07-29 | 2004-07-01 | Altana Pharma Ag | Novel salt of (S)-PANTOPRAZOLE |
| AU2003262992A1 (en) * | 2002-08-30 | 2004-03-19 | Reddy's Laboratories Limited | Amorphous hydrates of esomeprazole magnesium and process for the preparation thereof |
| WO2004037253A1 (en) * | 2002-10-22 | 2004-05-06 | Ranbaxy Laboratories Limited | Amorphous form of esomeprazole salts |
| JP2006513239A (ja) * | 2002-12-23 | 2006-04-20 | セルテック アメリカズ， インコーポレイテッド | 酸不安定性薬剤含有組成物 |
| TWI367759B (en) * | 2003-02-20 | 2012-07-11 | Santarus Inc | A novel formulation, omeprazole antacid complex-immediate release, for rapid and sustained suppression of gastric acid |
| WO2004099182A1 (en) * | 2003-05-05 | 2004-11-18 | Ranbaxy Laboratories Limited | Zinc salt of (s)-omeprazole |
| CN1842525A (zh) * | 2003-05-05 | 2006-10-04 | 兰贝克赛实验室有限公司 | 苯并咪唑衍生物的钡盐 |
| US8993599B2 (en) * | 2003-07-18 | 2015-03-31 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
| EP1648416A4 (en) * | 2003-07-18 | 2012-03-28 | Santarus Inc | PHARMACEUTICAL FORMULATIONS FOR INHIBITING THE ACIDIC ACIDIFICATION AND MANUFACTURING AND USE METHOD |
| US20050031700A1 (en) * | 2003-07-18 | 2005-02-10 | Sanatarus, Inc. | Pharmaceutical formulation and method for treating acid-caused gastrointestinal disorders |
| AR046400A1 (es) * | 2003-07-23 | 2005-12-07 | Altana Pharma Ag | Sales de pantoprazol |
| CN100457104C (zh) * | 2003-07-23 | 2009-02-04 | 尼科梅德有限责任公司 | 质子泵抑制剂的碱性盐 |
| TWI372066B (en) | 2003-10-01 | 2012-09-11 | Wyeth Corp | Pantoprazole multiparticulate formulations |
| US20070292498A1 (en) * | 2003-11-05 | 2007-12-20 | Warren Hall | Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers |
| SE0400410D0 (sv) | 2004-02-20 | 2004-02-20 | Astrazeneca Ab | New compounds |
| WO2005082888A1 (en) * | 2004-03-01 | 2005-09-09 | Milen Merkez Ilac Endustrisi A.S. | Process for the preparation of magnesium salt of omeprazole |
| US8815916B2 (en) * | 2004-05-25 | 2014-08-26 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
| US8906940B2 (en) * | 2004-05-25 | 2014-12-09 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
| US20050267159A1 (en) * | 2004-05-28 | 2005-12-01 | Aaipharma, Inc. | Magnesium complexes of S-omeprazole |
| DK1748998T3 (da) * | 2004-05-28 | 2010-05-10 | Hetero Drugs Ltd | Ny stereoselektiv syntese af benzimidazolsulfoxider |
| AU2005257709C1 (en) | 2004-06-24 | 2011-02-24 | Astrazeneca Ab | New process for the preparation of crystal modifications for use in the preparation of esomeprazole sodium salt |
| US20060024362A1 (en) | 2004-07-29 | 2006-02-02 | Pawan Seth | Composition comprising a benzimidazole and process for its manufacture |
| AU2005268056B2 (en) | 2004-08-06 | 2008-07-31 | Eisai R&D Management Co., Ltd. | Salts of benzimidazole derivative with amines and process for production thereof |
| CN101111233A (zh) | 2004-12-23 | 2008-01-23 | 兰贝克赛实验室有限公司 | 稳定的口服苯并咪唑组合物及其制备方法 |
| WO2006073779A1 (en) * | 2004-12-30 | 2006-07-13 | Transform Phamaceuticals, Inc. | Novel omeprazole forms and related methods |
| US20080279951A1 (en) * | 2005-02-02 | 2008-11-13 | Rajesh Gandhi | Stable Oral Benzimidazole Compositions Prepared by Non-Aqueous Layering Process |
| WO2006120520A1 (en) * | 2005-05-06 | 2006-11-16 | Glenmark Pharmaceuticals Limited | Esomeprazole strontium salt, process for its preparation and pharmaceutical compositions containing same |
| US7803817B2 (en) | 2005-05-11 | 2010-09-28 | Vecta, Ltd. | Composition and methods for inhibiting gastric acid secretion |
| US7981908B2 (en) | 2005-05-11 | 2011-07-19 | Vecta, Ltd. | Compositions and methods for inhibiting gastric acid secretion |
| EP1891043A1 (en) | 2005-06-15 | 2008-02-27 | Hetero Drugs Limited | Amorphous esomeprazole hydrate |
| US20070043085A1 (en) * | 2005-08-19 | 2007-02-22 | Glenmark Pharmaceuticals Limited | Process for the preparation of amorphous form of neutral esomeprazole |
| EP1785135A1 (en) | 2005-11-10 | 2007-05-16 | Laboratorios Del Dr. Esteve, S.A. | New stabilized galenic formulations comprising lansoprazole and their preparation |
| EP1801110A1 (en) | 2005-12-22 | 2007-06-27 | KRKA, tovarna zdravil, d.d., Novo mesto | Esomeprazole arginine salt |
| ES2281292B1 (es) * | 2006-03-08 | 2008-06-16 | Quimica Sintetica S.A. | Nuevas sales de esomeprazol. procedimiento de preparacion y composiciones farmaceuticas que las comprenden. |
| US7786309B2 (en) | 2006-06-09 | 2010-08-31 | Apotex Pharmachem Inc. | Process for the preparation of esomeprazole and salts thereof |
| AU2007278986B2 (en) | 2006-07-25 | 2010-09-16 | Vecta, Ltd. | Compositions and methods for inhibiting gastric acid secretion using derivatives of small dicarboxylic acids in combination with PPI |
| CA2665226C (en) | 2006-10-05 | 2014-05-13 | Santarus, Inc. | Novel formulations of proton pump inhibitors and methods of using these formulations |
| US20090092658A1 (en) * | 2007-10-05 | 2009-04-09 | Santarus, Inc. | Novel formulations of proton pump inhibitors and methods of using these formulations |
| EP2486910A3 (en) | 2006-10-27 | 2012-08-22 | The Curators Of The University Of Missouri | Multi-chambered apparatus comprising a dispenser head |
| PL2124884T3 (pl) | 2006-12-22 | 2020-01-31 | Ironwood Pharmaceuticals, Inc. | Metody i kompozycje do leczenia zaburzeń przełyku |
| US20080194307A1 (en) * | 2007-02-13 | 2008-08-14 | Jeff Sanger | Sports-based game of chance |
| NZ579136A (en) | 2007-02-21 | 2012-05-25 | Cipla Ltd | Process for the preparation of esomeprazole magnesium dihydrate |
| ATE534643T1 (de) * | 2007-06-07 | 2011-12-15 | Aurobindo Pharma Ltd | Verbessertes verfahren zur herstellung eines optisch aktiven protonenpumpenhemmers |
| EP2195309A4 (en) * | 2007-10-08 | 2013-04-24 | Hetero Drugs Ltd | SALT POLYMORPHS OF THE ESOMEPRAZOLE |
| CA2716367C (en) | 2008-02-20 | 2015-05-26 | The Curators Of The University Of Missouri | Composition comprising a combination of omeprazole and lansoprazole, and a buffering agent, and methods of using same |
| US8911787B2 (en) | 2008-02-26 | 2014-12-16 | Ranbaxy Laboratories Limited | Stable oral benzimidazole compositions and process of preparation thereof |
| WO2009137648A1 (en) * | 2008-05-09 | 2009-11-12 | Aptapharma, Inc. | Multilayer proton pump inhibitor tablets |
| US20090280173A1 (en) * | 2008-05-09 | 2009-11-12 | Ishwar Chauhan | Multilayer Omeprazole Tablets |
| EP2147918A1 (en) | 2008-07-21 | 2010-01-27 | LEK Pharmaceuticals D.D. | Process for the preparation of S-omeprazole magnesium in a stable form |
| CH699302B1 (de) * | 2008-08-11 | 2012-03-15 | Mepha Gmbh | Orale pharmazeutische Formulierung für Omeprazol, enthaltend eine spezifische Trennschicht. |
| CA2736547C (en) | 2008-09-09 | 2016-11-01 | Pozen Inc. | Method for delivering a pharmaceutical composition to patient in need thereof |
| US8354541B2 (en) * | 2008-11-18 | 2013-01-15 | Hetero Research Foundation | Optical purification of esomeprazole |
| WO2010122583A2 (en) | 2009-04-24 | 2010-10-28 | Rubicon Research Private Limited | Oral pharmaceutical compositions of acid labile substances |
| EA201290026A1 (ru) | 2009-06-25 | 2012-07-30 | Астразенека Аб | Способ лечения пациента, имеющего риск развития язвы, связанной с приемом нестероидных противовоспалительных средств (nsaid) |
| KR20120093140A (ko) * | 2009-06-25 | 2012-08-22 | 포젠 인크. | 아스피린 치료를 필요로 하는 환자의 치료 방법 |
| WO2011058569A1 (en) | 2009-11-12 | 2011-05-19 | Hetero Research Foundation | Process for the resolution of omeprazole |
| EP2345408A3 (en) | 2010-01-08 | 2012-02-29 | Dr. Reddy's Laboratories Ltd. | Acid labile drug formulations |
| FR2967353B1 (fr) * | 2010-11-16 | 2013-08-16 | Centre Nat Rech Scient | Derives de quinolinone |
| CN102351846B (zh) * | 2011-09-07 | 2012-08-22 | 周晓东 | 一种新的奥美拉唑钠化合物及其药物组合物 |
| WO2013081566A1 (en) | 2011-11-25 | 2013-06-06 | Mahmut Bilgic | A formulation comprising benzimidazole |
| EP2797600A4 (en) | 2011-12-28 | 2015-09-16 | Pozen Inc | IMPROVED COMPOSITIONS AND METHODS OF DISTRIBUTING OMEPRAZOLE AND ACETYL SALICYLIC ACID |
| CN104203938A (zh) | 2012-01-21 | 2014-12-10 | 朱比兰特生命科学有限公司 | 用于制备2-吡啶基甲基亚硫酰基苯并咪唑、它们的类似物和光学活性对映体的方法 |
| CN105338958A (zh) | 2013-01-15 | 2016-02-17 | 铁木医药有限公司 | 胆汁酸螯合剂的胃内滞留缓释口服剂型 |
| EP2956149B1 (en) * | 2013-02-13 | 2019-06-19 | RedHill Biopharma Ltd. | Pharmaceutical compositions for the treatment of helicobacter pylori |
| GB201306720D0 (en) | 2013-04-12 | 2013-05-29 | Special Products Ltd | Formulation |
| EP2929885A1 (en) | 2014-04-11 | 2015-10-14 | Sanovel Ilac Sanayi ve Ticaret A.S. | Pharmaceutical combinations of rivaroxaban and proton pump inhibitors |
| WO2015155281A1 (en) | 2014-04-11 | 2015-10-15 | Sanovel Ilac Sanayi Ve Ticaret A.S. | Pharmaceutical combinations of dabigatran and proton pump inhibitors |
| CN104045627A (zh) * | 2014-05-21 | 2014-09-17 | 丽珠医药集团股份有限公司 | 一种奥美拉唑纯化方法 |
| US20180015118A1 (en) | 2015-02-03 | 2018-01-18 | Ironwood Pharmaceuticals, Inc. | Methods of treating upper gastrointestinal disorders in ppi refractory gerd |
| US20170042806A1 (en) | 2015-04-29 | 2017-02-16 | Dexcel Pharma Technologies Ltd. | Orally disintegrating compositions |
| US10076494B2 (en) | 2016-06-16 | 2018-09-18 | Dexcel Pharma Technologies Ltd. | Stable orally disintegrating pharmaceutical compositions |
| EP4598528A1 (en) | 2022-10-04 | 2025-08-13 | Arsenil Zabirnyk | Inhibition of aortic valve calcification |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1234058A (enExample) * | 1968-10-21 | 1971-06-03 | ||
| US4045564A (en) * | 1974-02-18 | 1977-08-30 | Ab Hassle | Benzimidazole derivatives useful as gastric acid secretion inhibitors |
| SE416649B (sv) * | 1974-05-16 | 1981-01-26 | Haessle Ab | Forfarande for framstellning av foreningar som paverkar magsyrasekretionen |
| CA1085392A (en) * | 1976-03-25 | 1980-09-09 | Masayuki Narisada | Arylmalonamido-1-oxadethiacephalosporins |
| SE7804231L (sv) * | 1978-04-14 | 1979-10-15 | Haessle Ab | Magsyrasekretionsmedel |
| US4359465A (en) * | 1980-07-28 | 1982-11-16 | The Upjohn Company | Methods for treating gastrointestinal inflammation |
| US4472409A (en) * | 1981-11-05 | 1984-09-18 | Byk Gulden Lomberg Chemische Fabrik Gesellschaft Mit Beschrankter Haftung | 2-Pyridylmethyl thio(sulfinyl)benzimidazoles with gastric acid secretion inhibiting effects |
-
1983
- 1983-03-04 SE SE8301182A patent/SE8301182D0/xx unknown
-
1984
- 1984-02-16 IL IL70985A patent/IL70985A/xx not_active IP Right Cessation
- 1984-02-17 ZA ZA841202A patent/ZA841202B/xx unknown
- 1984-02-24 DK DK099584A patent/DK160044C/da not_active IP Right Cessation
- 1984-02-28 BG BG064457A patent/BG44538A3/xx unknown
- 1984-02-28 DE DE8484850066T patent/DE3462036D1/de not_active Expired
- 1984-02-28 DE DE2001199022 patent/DE10199022I2/de active Active
- 1984-02-28 AT AT84850066T patent/ATE24907T1/de active
- 1984-02-28 EP EP84850066A patent/EP0124495B1/en not_active Expired
- 1984-02-29 NO NO840772A patent/NO160204C/no not_active IP Right Cessation
- 1984-03-01 PH PH30317A patent/PH21352A/en unknown
- 1984-03-01 IS IS2887A patent/IS1363B6/is unknown
- 1984-03-02 ES ES530242A patent/ES8500934A1/es not_active Expired
- 1984-03-02 IE IE514/84A patent/IE57326B1/en not_active IP Right Cessation
- 1984-03-02 SU SU843710408A patent/SU1314953A3/ru active
- 1984-03-02 JP JP59038921A patent/JPS59167587A/ja active Granted
- 1984-03-02 PL PL1984246492A patent/PL142748B1/pl unknown
- 1984-03-02 CS CS841515A patent/CS241150B2/cs unknown
- 1984-03-02 GR GR73990A patent/GR79828B/el unknown
- 1984-03-02 GB GB08405511A patent/GB2137616B/en not_active Expired
- 1984-03-02 PT PT78191A patent/PT78191B/pt unknown
- 1984-03-02 ES ES000530242D patent/ES8500934B9/es active Active
- 1984-03-02 AU AU25257/84A patent/AU563842B2/en not_active Expired
- 1984-03-02 SI SI8410397A patent/SI8410397A8/sl unknown
- 1984-03-02 YU YU397/84A patent/YU43345B/xx unknown
- 1984-03-02 RO RO84113806A patent/RO88721A/ro unknown
- 1984-03-02 NZ NZ207348A patent/NZ207348A/en unknown
- 1984-03-02 HU HU84845A patent/HU193557B/hu unknown
- 1984-03-02 CA CA000448761A patent/CA1264751A/en not_active Expired - Lifetime
- 1984-03-02 DD DD84260523A patent/DD221459A5/de unknown
- 1984-03-02 FI FI840851A patent/FI83649C/fi not_active IP Right Cessation
- 1984-03-03 KR KR1019840001074A patent/KR870001005B1/ko not_active Expired
- 1984-03-03 JO JO19841425A patent/JO1425B1/en active
- 1984-03-04 DZ DZ847097A patent/DZ615A1/fr active
- 1984-03-05 MA MA20272A patent/MA20050A1/fr unknown
-
1986
- 1986-04-21 US US06/854,739 patent/US4738974A/en not_active Expired - Lifetime
-
1987
- 1987-09-26 MY MYPI87001982A patent/MY102052A/en unknown
-
1990
- 1990-01-10 SG SG14/90A patent/SG1490G/en unknown
- 1990-02-22 HK HK135/90A patent/HK13590A/en not_active IP Right Cessation
-
1992
- 1992-03-09 SA SA92120418A patent/SA92120418B1/ar unknown
-
1993
- 1993-03-22 HR HRP-397/84A patent/HRP930428B1/xx not_active IP Right Cessation
- 1993-06-30 LV LV930867A patent/LV5503A3/xx unknown
- 1993-09-06 LT LTRP947A patent/LT2253B/xx not_active IP Right Cessation
-
1994
- 1994-02-25 BG BG098585A patent/BG60837B2/bg unknown
-
1996
- 1996-07-18 LV LV960280A patent/LV5801B4/xx unknown
-
2000
- 2000-10-05 NO NO2000010C patent/NO2000010I1/no unknown
- 2000-11-15 LU LU90677C patent/LU90677I2/fr unknown
- 2000-11-17 NL NL300027C patent/NL300027I2/nl unknown
Cited By (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6123962A (en) * | 1986-02-13 | 2000-09-26 | Takeda Chemical Industries, Inc. | Process for producing stabilized pharmaceutical composition |
| US6296875B1 (en) | 1986-02-13 | 2001-10-02 | Takeda Chemical Industries, Ltd. | Method for producing a granule |
| US6749864B2 (en) | 1986-02-13 | 2004-06-15 | Takeda Chemical Industries, Ltd. | Stabilized pharmaceutical composition |
| US6521256B2 (en) | 1986-02-13 | 2003-02-18 | Takeda Chemical Industries, Ltd. | Stabilized pharmaceutical composition |
| US5433959A (en) * | 1986-02-13 | 1995-07-18 | Takeda Chemical Industries, Ltd. | Stabilized pharmaceutical composition |
| US5639478A (en) * | 1986-02-13 | 1997-06-17 | Takeda Chemical Industries, Ltd. | Method to stabilize a pharmaceutical composition and its production |
| JPS62277322A (ja) * | 1986-02-13 | 1987-12-02 | Takeda Chem Ind Ltd | 安定化された腸溶性抗潰瘍固形組成物 |
| US5879708A (en) * | 1986-02-13 | 1999-03-09 | Takeda Chemical Industries, Ltd. | Stabilized pharmaceutical composition |
| US6380234B1 (en) | 1986-02-13 | 2002-04-30 | Takeda Chemical Industries, Ltd. | Stabilized pharmaceutical composition and its production |
| US6017560A (en) * | 1986-02-13 | 2000-01-25 | Takeda Chemical Industries, Ltd. | Process for producing stabilized pharmaceutical composition |
| JPS62258320A (ja) * | 1986-04-30 | 1987-11-10 | Yoshitomi Pharmaceut Ind Ltd | 内服用新規医薬製剤 |
| JPH05294831A (ja) * | 1986-04-30 | 1993-11-09 | Yoshitomi Pharmaceut Ind Ltd | 内服用新規医薬製剤 |
| JPH02138213A (ja) * | 1988-08-18 | 1990-05-28 | Takeda Chem Ind Ltd | 注射剤 |
| JP2007161734A (ja) * | 1997-05-30 | 2007-06-28 | Astrazeneca Ab | Ｓ−オメプラゾールの新規な形態 |
| JP2003512327A (ja) * | 1999-10-22 | 2003-04-02 | アストラゼネカ・アクチエボラーグ | 置換ベンズイミダゾール製剤 |
| JP2002114779A (ja) * | 2000-08-04 | 2002-04-16 | Takeda Chem Ind Ltd | ベンズイミダゾール化合物の塩およびその用途 |
| JP2005521693A (ja) * | 2002-03-05 | 2005-07-21 | アストラゼネカ・アクチエボラーグ | オメプラゾール及びエソメプラゾールのアルキルアンモニウム塩 |
| JP2011137014A (ja) * | 2003-02-24 | 2011-07-14 | Mitsubishi Tanabe Pharma Corp | テナトプラゾールの光学異性体および治療におけるその使用 |
| JP2006519224A (ja) * | 2003-02-24 | 2006-08-24 | 三菱ウェルファーマ株式会社 | テナトプラゾールの光学異性体および治療におけるその使用 |
| US8207190B2 (en) | 2003-02-24 | 2012-06-26 | Mitsubishi Tanabe Pharma Corporation | Enantiomer of tenatoprazole and the use thereof in therapy |
| JP4891064B2 (ja) * | 2003-02-24 | 2012-03-07 | 田辺三菱製薬株式会社 | テナトプラゾールの光学異性体および治療におけるその使用 |
| JP4787017B2 (ja) * | 2003-03-24 | 2011-10-05 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | スルホキシド誘導体またはその塩のアモルファスの製造方法 |
| US7754887B2 (en) | 2003-03-24 | 2010-07-13 | Eisai R&D Management Co., Ltd. | Process for production of sulfoxide derivatives or salts thereof in the amorphous state |
| WO2004085424A1 (ja) * | 2003-03-24 | 2004-10-07 | Eisai Co., Ltd. | スルホキシド誘導体またはその塩のアモルファスの製造方法 |
| JPWO2004085424A1 (ja) * | 2003-03-24 | 2006-06-29 | エーザイ株式会社 | スルホキシド誘導体またはその塩のアモルファスの製造方法 |
| JP2007504222A (ja) * | 2003-09-04 | 2007-03-01 | アストラゼネカ・アクチエボラーグ | オメプラゾール及びエソメプラゾールｉの新規な塩 |
| JP2007504223A (ja) * | 2003-09-04 | 2007-03-01 | アストラゼネカ・アクチエボラーグ | オメプラゾール及びエソメプラゾールｉｉの新規な塩 |
| JP2008502665A (ja) * | 2004-06-17 | 2008-01-31 | シデム ファーマ ソシエテ アノニム | Ｓ−テナトプラゾールナトリウム塩一水和物及び治療におけるその使用 |
| JP2008545768A (ja) * | 2005-06-08 | 2008-12-18 | レツク・フアーマシユーテイカルズ・デー・デー | オメプラゾールナトリウムの結晶性溶媒和物 |
| JP2009513625A (ja) * | 2005-10-26 | 2009-04-02 | ハンミ ファーム． シーオー．， エルティーディー． | Ｓ−オメプラゾールストロンチウム塩またはその水和物、その製造方法、及びこれを含む医薬組成物 |
| US8513426B2 (en) | 2005-10-26 | 2013-08-20 | Hanmi Science Co., Ltd | Crystalline S-omeprazole strontium hydrate, method for preparing same, and pharmaceutical composition containing same |
| US8586752B1 (en) | 2005-10-26 | 2013-11-19 | Hanmi Science Co., Ltd | Crystalline S-omeprazole strontium hydrate, method for preparing same, and pharmaceutical composition containing same |
| JP2009539830A (ja) * | 2006-06-07 | 2009-11-19 | アストラゼネカ・アクチエボラーグ | エソメプラゾールのアンモニウム塩の新規な製造方法 |
| JP2010054398A (ja) * | 2008-08-29 | 2010-03-11 | Seiko Clock Inc | 装飾装置及びからくり時計 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPS59167587A (ja) | オメプラゾ−ル化合物 | |
| HU226861B1 (en) | Magnesium salt of omeprazole | |
| HU226824B1 (en) | Optically active salts of pyridinyl-methyl-sulfinyl-1h-benzimidazol derivatives, pharmaceutical compositions containing them and process for producing them | |
| JPH05507714A (ja) | ジアルコキシ−ピリジニル−ベンズイミダゾール誘導体、その製造方法およびそれを含む医薬 | |
| HK132695A (en) | Anhdrous, crystalline sodium salt of 5-chloro-3-(2-thenoyl)-2-oxindole-1-carboxamide | |
| AU636866B2 (en) | Therapeutically active substituted benzimidazole and process for its preparation | |
| EP0173664A2 (en) | Biologically active benzimidazole compounds and process for their preparation | |
| JP2005527485A (ja) | 第Ｘａ因子インヒビターとして新規なＮ−［４−（１Ｈ−イミダゾール−１−イル）−２−フルオロフェニル］−３−（トリフルオロメチル）−１Ｈ−ピラゾール−５−カルボキサミド化合物 | |
| JPH09504557A (ja) | 新規なジアルコキシ−ピリジニル−ベンズイミダゾール誘導体 | |
| JPS6258335B2 (enExample) | ||
| CN102918050B (zh) | 肠顶端膜钠/磷协同转运的芳基氟磷酸酯抑制剂 | |
| JPS61183259A (ja) | 新規オキサルル酸誘導体及び該化合物を含有する血糖低下剤 | |
| OA10986A (en) | Crystalline pharmaceutical product | |
| JPS61122275A (ja) | 新規ヒダントイン誘導体及び該化合物を含有する医薬組成物 | |
| US2915431A (en) | 2-(2'-isopropyl-4'-chloro-5'-methyl)-phenoxymethyl-2-imidazoline and its pharmaceutical uses | |
| TWI876245B (zh) | (2R, 3S)-2-(3-(4,5-二氯-1H-苯并[d]咪唑-1-基)丙基)哌啶-3-醇的新穎酸加成鹽及晶形 | |
| NZ509170A (en) | Bispiperidines as antithrombotic agents | |
| LT3809B (en) | Therapeutically active fluoro substituted benzimidazoles, process for their preparation as well as their use | |
| JPH06500789A (ja) | イミダゾール誘導体、それらの製造方法および医薬組成物 | |
| JPH02240084A (ja) | １，５―ジ置換―１Ｈ―ピラゾロ〔３，４―ｂ〕ピラジン誘導体および該化合物を含有する抗腫瘍剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R153 | Grant of patent term extension |
Free format text: JAPANESE INTERMEDIATE CODE: R153 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080222 Year of fee payment: 17 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090222 Year of fee payment: 18 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100222 Year of fee payment: 19 |
|
| EXPY | Cancellation because of completion of term | ||
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100222 Year of fee payment: 19 |